A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives

Drug Metabolism and Disposition

Volumn 31, Issue 7, 2003, Pages 967-971

  Locuson II, Charles W ^a   Wahlstrom, Jan L ^c   Rock, Denise A ^b   Rock, Dan A ^b   Jones, Jeffrey P ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Department of Chemistry ^*  (United States)

^c Camitro Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPHOTERICIN B; ANION; BENZARONE; BENZBROMARONE; BENZIODARONE; BENZOYLPHENOL; CYTOCHROME P450; CYTOCHROME P450 2C9; GENTAMICIN; PHENOL DERIVATIVE; PHENYTOIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BINDING AFFINITY; BLEEDING; DRUG BINDING; DRUG CLEARANCE; DRUG SPECIFICITY; DRUG STRUCTURE; HALOGENATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIVER TOXICITY; PKA; PRIORITY JOURNAL; PROTEIN BINDING;

ARYL HYDROCARBON HYDROXYLASES; BENZBROMARONE; BINDING SITES; MOLECULAR PROBES; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; SENSITIVITY AND SPECIFICITY;

EID: 0037636387     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.7.967     Document Type: Article

References (32)

1. Bush E, Low L, and Trager W (1983) A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom 10:395-398.
2. De Groot M, Alex A, and Jones B (2002) Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 45:1983-1993.
3. De Vries J, Walter-Sack I, Voss A, Forster W, llisistegui Pons P, Stoetzer F, Spraul M, Ackermann M, and Moyna G (1993) Metabolism of benzbromarone in man: structures of new oxidative metabolites, 6-hydroxy- and I' -oxo-benzbromarone and the enantioselective formation and elimination of I'-hydroxybenzbromarone. Xenobiotica 23:1435-1450.
4. Ekins S, Bravi G, Binkley S, Gillespie J, Ring B, Wikel J, and Wrighton S (2000) Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 28:994-1002.
5. Gnaim J and Sheldon R (1995) Highly regioselective ortho-chlorination of phenol with surfuryl chloride in the presence of amines. Tetrahedron Lett 36:3893-3896.
6. Haining R. Hunter A, Veronese M, Trager W, and Rettie A (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
7. Haining R, Jones J, Henne K, Fisher M, Koop D, Trager W, and Rettie A (1999) Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry 38:3285-3292.
8. Hautekeete M, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, and Kloppel G (1995) Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver 15:25-29.
9. He M, Korzekwa K, Jones J, Rettie A, and Trager W (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16-28.
10. Hutzler J, Kolwankar D, Hummel M, and Tracy T (2002) Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 30:1194-1200.
11. Johnson E, Wester M, and Stout C (2002) The structure of microsomal cytochrome P450 2C5: a steroid and drug metabolizing enzyme. Endocr Res 28:435-441.
12. Jones B, Hawksworth G, Home V, Newlands A, Morsman J, Tute M, and Smith D (1996a) Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos 24:260-266.
13. Jones J, He M, Trager W, and Rettie A (1996b) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 24:1-6.
14. Kudo T and Sudo H (1995) Enhancement of anticoagulant effect of warfarin by benzbromarone, an uricosuric drug. Nippon Kessen Shiketsu Gakkaishi 6:119-124.
15. Mancy A. Broto P, Dijols S, Dansette P, and Mansuy D (1995) The substrate binding site of human liver cytochrome P450 2C9 - an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34:10365-10375.
16. Mancy A, Dijols S, Poli S, Guengerich P, and Mansuy D (1996) Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35:16205-16212.
17. Miners J and Birkett D (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
18. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
19. O'Reilly R, Trager W, Rettie A, and Goulart D (1987) Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 42:290-294.
20. Ortiz de Montellano P (1995) Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum, New York.
21. Pearson D, Wysong R, and Breder C (1967) Ortho bromination of phenols. J Org Chem 32:2358-2360.
22. Poli-Scaife S, Attais R, Dansette P, and Mansuy D (1997) The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 36:12672-12682.
23. Rao S, Aoyama R, Schrag M, Trager W, Rettie A, and Jones J (2000) A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 43:2789-2796.
24. Rettie A, Korzekwa K, Kunze K, Lawrence R, Eddy A, Aoyama T, Gelboin H, Gonzalez F, and Trager W (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
25. Ridderstrom M, Masimirembwa C, Trump-Kallmeyer S, Ahlefelt M, Otter C, and Andersson T (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem Biophys Res Commun 270:983-987.
26. Rock D and Jones J (2001) Inexpensive purification of p450 reductase and other proteins using 2′, 5′-adenosine diphosphate agarose affinity columns. Protein Expression Purif22:82-83.
27. Sion R (1985) Synthesis of 2-n butyl 3-(3, 5-125 diiodo 4-(N,N-diethylamino 2-ethoxybenzoyl)) benzofuran hydrochloride (1251 amiodarone). J Labelled Compd Radiopharm 22:799-805.
28. Smith D and Jones B (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098.
29. Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H, Yasumori T, and Echizen H (1999) Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66:569-581.
30. Tracy T, Hutzler J, Haining R, Rettie A, Hummel M, and Dickmann L (2001) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385-390.
31. van der Klauw M, Houtman P, Stricker B, and Spoelstra P (1994) Hepatic injury caused by benzbromarone. J Hepatol 20:376-379.
32. Williams P, Cosme J, Sridhar V, Johnson E, and McRee D (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131.